| Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders |
276 |
| Neurofilaments as biomarkers in neurological disorders |
208 |
| Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums |
143 |
| Tau-targeting therapies for Alzheimer disease |
136 |
| Ageing as a risk factor for neurodegenerative disease |
134 |
| A critical appraisal of amyloid-beta targeting therapies for Alzheimer disease |
121 |
| CGRP as the target of new migraine therapies - successful translation from bench to clinic |
115 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies |
93 |
| Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic |
91 |
| Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease |
90 |
| C9orf72-mediated ALS and FTD: multiple pathways to disease |
85 |
| Antisense oligonucleotides: the next frontier for treatment of neurological disorders |
78 |
| Myelin oligodendrocyte glycoprotein antibodies in neurological disease |
77 |
| Deep brain stimulation: current challenges and future directions |
74 |
| Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy |
71 |
| Exosomes-beyond stem cells for restorative therapy in stroke and neurological injury |
68 |
| Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies |
66 |
| Idiopathic REM sleep behaviour disorder and neurodegeneration - an update |
63 |
| Sex differences in Alzheimer disease - the gateway to precision medicine |
63 |
| TREM2-a key player in microglial biology and Alzheimer disease |
56 |
| Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment |
53 |
| Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease |
52 |
| Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions |
51 |
| Therapeutic developments for Duchenne muscular dystrophy |
48 |
| Immunoneuropsychiatry - novel perspectives on brain disorders |
48 |
| Genetic and molecular epidemiology of adult diffuse glioma |
48 |
| Emerging therapies in Parkinson disease - repurposed drugs and new approaches |
41 |
| Multidimensional communication in the microenvirons of glioblastoma |
40 |
| Cerebral small vessel disease: from a focal to a global perspective |
39 |
| Diagnosis and management of Guillain-Barre syndrome in ten steps |
38 |
| Teleneurology and mobile technologies: the future of neurological care |
38 |
| Treatment of multiple sclerosis - success from bench to bedside |
38 |
| Seizure prediction - ready for a new era |
37 |
| Dementia in Down syndrome: unique insights for Alzheimer disease research |
35 |
| Spinocerebellar ataxias: prospects and challenges for therapy development |
34 |
| POLG-related disorders and their neurological manifestations |
34 |
| Does inflammation have a role in migraine? |
33 |
| Advances in therapy for spinal muscular atrophy: promises and challenges |
32 |
| Olfactory and other sensory impairments in Alzheimer disease |
32 |
| Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction |
31 |
| The pro-remyelination properties of microglia in the central nervous system |
31 |
| Epidemiology and treatment of multiple sclerosis in elderly populations |
31 |
| Bridging biophysics and neurology: aberrant phase transitions in neurodegenerative disease |
31 |
| Axonal transport and neurological disease |
29 |
| Traumatic brain injury: sex, gender and intersecting vulnerabilities |
29 |
| Spatial navigation deficits - overlooked cognitive marker for preclinical Alzheimer disease? |
28 |
| The current role of MRI in differentiating multiple sclerosis from its imaging mimics |
26 |
| Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting |
24 |
| Haemoglobin scavenging in intracranial bleeding: biology and clinical implications |
23 |
| Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges |
22 |
| Post-traumatic headache: epidemiology and pathophysiological insights |
22 |
| Advances in meningioma genetics: novel therapeutic opportunities |
22 |
| Thrombo-inflammation in acute ischaemic stroke - implications for treatment |
21 |
| Neuroinflammation in frontotemporal dementia |
21 |
| Long-term outcomes of deep brain stimulation in Parkinson disease |
20 |
| Protecting the ischaemic penumbra as an adjunct to thrombectomy for acute stroke |
20 |
| Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis |
19 |
| The complex aetiology of cerebral palsy |
18 |
| Immunotherapy in myasthenia gravis in the era of biologics |
18 |
| Biological insights from the premonitory symptoms of migraine |
17 |
| Lafora disease - from pathogenesis to treatment strategies |
17 |
| Chronic traumatic encephalopathy - confusion and controversies |
17 |
| The translational landscape in spinal cord injury: focus on neuroplasticity and regeneration |
16 |
| Japanese encephalitis - the prospects for new treatments |
16 |
| Therapeutic landscape for Batten disease: current treatments and future prospects |
16 |
| The role of sensory information in the pathophysiology of focal dystonias |
15 |
| A stocked toolbox for understanding the role of astrocytes in disease |
15 |
| The metabolic face of migraine - from pathophysiology to treatment |
15 |
| Changing concepts in presurgical assessment for epilepsy surgery |
14 |
| Neurological disorders of gait, balance and posture: a sign-based approach |
13 |
| Chronic inflammation in multiple sclerosis - seeing what was always there |
13 |
| Complex regional pain syndrome - phenotypic characteristics and potential biomarkers |
12 |
| Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond |
12 |
| Adulthood leukodystrophies |
11 |
| Neuroimmune disorders of the central nervous system in children in the molecular era |
11 |
| Genotype-phenotype links in frontotemporal lobar degeneration |
11 |
| When encephalitogenic T cells collaborate with microglia in multiple sclerosis |
11 |
| Physiological changes in neurodegeneration - mechanistic insights and clinical utility |
10 |
| Traumatic and nontraumatic spinal cord injury: pathological insights from neuroimaging |
10 |
| NREM sleep parasomnias as disorders of sleep-state dissociation |
10 |
| Nontraumatic intracerebral haemorrhage in young adults |
10 |
| Genetic drivers of cerebral blood flow dysfunction in TBI: a speculative synthesis |
10 |
| From molecules to medicines: the dawn of targeted therapies for genetic epilepsies |
9 |
| Early-life adversity and neurological disease: age-old questions and novel answers |
9 |
| SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases |
8 |
| Parkinson's disease - the story of an eponym |
8 |
| A unifying motor control framework for task-specific dystonia |
7 |
| The promise of technology in the future of dementia care |
7 |
| Neurological manifestations of organic acidurias |
7 |
| Paediatric migraine: evidence-based management and future directions |
6 |
| Promises and limitations of immune cell-based therapies in neurological disorders |
6 |
| Dementia with Lewy bodies - from scientific knowledge to clinical insights |
6 |
| The role of thymic tolerance in CNS autoimmune disease |
4 |
| A cross-species approach to disorders affecting brain and behaviour |
4 |
| The role of neurologists in tackling the opioid epidemic |
3 |
